photo of

Details

Role Co-Grp Leader/Principal Research Fellow
Research area Genomic Medicine

Contact

Associate Professor Jonathan Payne is co-lead of the Brain & Mind Research Group at the Murdoch Children's Research Institute, where he leads the Genetics and Neurodevelopment Team and sits on the steering committee of the Neurodevelopment Flagship. He is a practicing senior clinical neuropsychologist at the Royal Children's Hospital and an Honorary Principal Research Fellow in the Department of Paediatrics, University of Melbourne.

Associate Professor Payne's research draws on a range of cognitive, behavioural, neuroimaging, and laboratory protocols to understand how genetic variants can affect brain development and increase the risk for neurodevelopmental disorders. He is also an experienced trialist and leads several pharmacological and non-pharmacological clinical trials.
Associate Professor Jonathan Payne is co-lead of the Brain & Mind Research Group at the Murdoch Children's Research Institute, where he leads the Genetics and Neurodevelopment Team and sits on the steering committee of the Neurodevelopment Flagship....
Associate Professor Jonathan Payne is co-lead of the Brain & Mind Research Group at the Murdoch Children's Research Institute, where he leads the Genetics and Neurodevelopment Team and sits on the steering committee of the Neurodevelopment Flagship. He is a practicing senior clinical neuropsychologist at the Royal Children's Hospital and an Honorary Principal Research Fellow in the Department of Paediatrics, University of Melbourne.

Associate Professor Payne's research draws on a range of cognitive, behavioural, neuroimaging, and laboratory protocols to understand how genetic variants can affect brain development and increase the risk for neurodevelopmental disorders. He is also an experienced trialist and leads several pharmacological and non-pharmacological clinical trials.

Top Publications

  • Zendarski, N, Galligan, R, Coghill, D, Payne, JM, De Luca, CR, Mulraney, M. The Associations between Child Irritability, Parental Distress, Parental Irritability and Family Functioning in Children Accessing Mental Health Services. Journal of Child and Family Studies 32(1) : 288 -300 2023
    view publication
  • de Blank, PMK, Gross, AM, Akshintala, S, Blakeley, JO, Bollag, G, Cannon, A, Dombi, E, Fangusaro, J, Gelb, BD, Hargrave, D, et al. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.. Neuro Oncol 24(11) : 1845 -1856 2022
    view publication
  • Rance, G, Maier, A, Zanin, J, Haebich, KM, North, KN, Orsini, F, Dabscheck, G, Delatycki, MB, Payne, JM. A randomized controlled trial of remote microphone listening devices to treat auditory deficits in children with neurofibromatosis type 1.. Neurol Sci 43(9) : 5637 -5641 2022
    view publication
  • Mulraney, M, Sciberras, E, Payne, JM, De Luca, C, Mills, J, Tennant, M, Coghill, D. Collaborative and Proactive Solutions compared with usual care to treat irritability in children and adolescents: a pilot randomized controlled trial. Clinical Psychologist 26(2) : 231 -239 2022
    view publication
  • Haebich, KM, Dao, DP, Pride, NA, Barton, B, Walsh, KS, Maier, A, Chisholm, AK, Darke, H, Catroppa, C, Malarbi, S, et al. The mediating role of ADHD symptoms between executive function and social skills in children with neurofibromatosis type 1.. Child Neuropsychol 28(3) : 318 -336 2022
    view publication

Page 3 of 14